source
- Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program droppedAclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…
- George Church departs AI startup as Ira Mellman advances immunotherapy effortsThe latest Endpoints Weekly notes that geneticist George Church has left the artificial-intelligence startup he co-founded, signaling a shift in his focus. The newsletter also highlights that immu…